175 related articles for article (PubMed ID: 11493879)
1. Drugs firms inflate research costs, watchdog says.
Knight J
Nature; 2001 Aug; 412(6847):571. PubMed ID: 11493879
[No Abstract] [Full Text] [Related]
2. [Does the public sector have an independent research role in the development of drugs?].
Poulsen HE; Grønlykke TB
Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
[TBL] [Abstract][Full Text] [Related]
3. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
4. What does R&D really cost?
Huff B
GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
[No Abstract] [Full Text] [Related]
5. Firms seek new models to access public equity.
Mitchell P
Nat Biotechnol; 2009 Oct; 27(10):878-9. PubMed ID: 19816432
[No Abstract] [Full Text] [Related]
6. US drug industry hurt by rising research costs and slumping prices, report says.
Rafuse J
CMAJ; 1994 Apr; 150(8):1306. PubMed ID: 8162554
[No Abstract] [Full Text] [Related]
7. Attrition and translation.
Duyk G
Science; 2003 Oct; 302(5645):603-5. PubMed ID: 14576424
[TBL] [Abstract][Full Text] [Related]
8. The cost of developing new drugs.
Oncology (Williston Park); 1992 Jan; 6(1):142-3. PubMed ID: 1531601
[No Abstract] [Full Text] [Related]
9. Obama says more money.
Tollefson J
Nature; 2009 Apr; 458(7242):1085. PubMed ID: 19407760
[No Abstract] [Full Text] [Related]
10. Introducing new contraceptives.
Segal SJ; Coutinho E
Draper Fund Rep; 1986 Dec; (15):27-32. PubMed ID: 12341234
[TBL] [Abstract][Full Text] [Related]
11. Public biotech 2008--the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2009 Aug; 27(8):710-21. PubMed ID: 19668175
[TBL] [Abstract][Full Text] [Related]
12. Medicine. A portfolio model of drug development for tuberculosis.
Glickman SW; Rasiel EB; Hamilton CD; Kubataev A; Schulman KA
Science; 2006 Mar; 311(5765):1246-7. PubMed ID: 16513969
[No Abstract] [Full Text] [Related]
13. Cost of new drugs.
Goozner M
Health Aff (Millwood); 2005; 24(3):883-4; author reply 884-5. PubMed ID: 15886185
[No Abstract] [Full Text] [Related]
14. Public sector seeks to bridge 'valley of death'.
Moran N
Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
[No Abstract] [Full Text] [Related]
15. The Human Genome Project: a public good.
Hudson K
Health Matrix Clevel; 2002; 12(2):367-75. PubMed ID: 12430360
[No Abstract] [Full Text] [Related]
16. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
17. Global health. Public-private partnerships proliferate.
Cohen J
Science; 2006 Jan; 311(5758):167. PubMed ID: 16410497
[No Abstract] [Full Text] [Related]
18. The real cost of development.
GMHC Treat Issues; 2001; 15(7-8):16. PubMed ID: 11548510
[No Abstract] [Full Text] [Related]
19. Public-private partnership: from there to here.
Croft SL
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
[TBL] [Abstract][Full Text] [Related]
20. Capitalizing on commercialization: should congress revisit the Bayh-Dole Act?
Bruckbauer S
J Natl Cancer Inst; 2003 Oct; 95(19):1429-31. PubMed ID: 14519745
[No Abstract] [Full Text] [Related]
[Next] [New Search]
